Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis

Abstract

BVAS for GPA ≥ 9.5 was an independent predictor of refractory disease during follow-up duration ≥ 12 weeks.

Systemic immune‐inflammation index could estimate the cross‐sectional high activity and the poor outcomes in immunosuppressive drug‐naïve patients with antineutrophil cytoplasmic antibody‐associated vasculitis

“…On the other hand, how can SII at diagnosis predict relapse or ESRD in AAV patients? In terms of relapse, we previously, proved that the initial BVAS is associated with poor prognosis of MPA and GPA in Korean patients . In this study, we elucidated SII at diagnosis could estimate severe AAV at diagnosis (BVAS at diagnosis ≥16).…”

“…In terms of relapse, we previously, proved that the initial BVAS is associated with poor prognosis of MPA and GPA in Korean patients. 23,24 In this study, we elucidated SII at diagnosis could estimate severe AAV at diagnosis (BVAS at diagnosis ≥16). Therefore, we conclude that SII at diagnosis based on BVAS could predict relapse of AAV during follow-up in the same way by which BVAS at diagnosis could contribute to predicting it.…”

Red Blood Cell Distribution Width Can Predict Vasculitis Activity and Poor Prognosis in Granulomatosis with Polyangiitis

“…Since BVAS for GPA, FFS (1996), FFS (2009), and ENT symptoms were significantly related to RDW, we divided GPA patients into groups according to BVAS ≥7 or <7, FFS (1996) ≥1 or <1, FFS (2009) ≥1 or <1, RDW ≥15.4% or <15.4%, and the presence or absence of ENT manifestation based on our previous studies. 16 17 18 We used univariate and multivariate Cox hazards models to analyse the potential for predicting the prognosis of GPA in disease processes. In terms of relapse of GPA, there was no statistically significant predictor among them.…”

“…We retrospectively reviewed the electronic medical records of 150 patients with AAV registered in the Severance Hospital Autoimmune Vasculitides cohort according to the following inclusion criteria: 16 17 18 19 1) patients who had been initially diagnosed with MPA, GPA, or EGPA from October 2000 to January 2017 at the Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital; 2) patients who had been follow-up for more than 12 weeks after the first diagnosis of AAV in our institute; 3) patients who had fulfilled the 2012 revised CHCC or the 2007 EMA algorithm for MPA 1 3 and who had met the ACR 1990 criteria for the classification for GPA and EGPA; 4 5 4) patients who had the initial results of MPO-ANCA or PR3-ANCA, but not ANCAs by immunofluorescence assay [IFA, perinuclear (P)-ANCA and cytoplasmic (C)-ANCA], and those who did not have both ANCAs; 5) patients who had not been accompanied by any medical conditions that would influence the positivity of MPO-ANCA or PR3-ANCA or RDW; 11 20 21 6) patients who had never received medications for medical conditions mentioned above upon searching by the Korean Drug Utilization Review (DUR) system at diagnosis; and 7) patients whose medical records contained accurate descriptions enough to calculate BVAS or BVAS for GPA and FFS (1996) and FFS (2009) on the same day of blood collection for laboratory tests at diagnosis. 6 7 9 10 This study was approved by the Institutional Review Board of Severance Hospital (IRB no.…”

“…We previously reported that BVAS ≥9.5 at diagnosis is associated with refractory disease in Korean patients with GPA. 17 However, because we focused on the potential of RDW to reflect cross-sectional activity of GPA, rather than predict refractory disease of GPA, we set the cut-off of BVAS for severe disease at 7, the highest quartile of BVAS for GPA. Remission was defined as absence of disease activity attributable to active disease qualified by the need for on-going stable maintenance immunosuppressive therapy.…”